Zobrazeno 1 - 10
of 7 019
pro vyhledávání: '"immune related adverse events"'
Autor:
David Mao, Anne S. Reiner, Xi Chen, Jae Park, Martina Pennisi, Miguel-Angel Perales, Edward K. Avila, Bianca D. Santomasso
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Patients who develop chimeric antigen receptor (CAR) T-cell-related immune effector cell-associated neurotoxicity syndrome (ICANS) frequently undergo evaluation with electroencephalography (EEG). We hypothesize that EEG features and Synek sc
Externí odkaz:
https://doaj.org/article/ec262d90bc1f4fecb5981ad4f7aba238
Autor:
Ryo Izumi, Toru Hashimoto, Hiroshi Kisanuki, Kei Ikuta, Wataru Otsuru, Soshun Asakawa, Shoei Yamamoto, Kayo Misumi, Takeo Fujino, Keisuke Shinohara, Shouji Matsushima, Kazuya Hosokawa, Shunsuke Katsuki, Taro Mori, Mikiko Hashisako, Yuki Tateishi, Takeshi Iwasaki, Yoshinao Oda, Shintaro Kinugawa, Kohtaro Abe
Publikováno v:
Cardio-Oncology, Vol 10, Iss 1, Pp 1-8 (2024)
Abstract The advent of immune checkpoint inhibitors (ICIs) has significantly improved cancer treatment. With the increasing use of ICIs, ICI-related myocarditis has been recognized. However, an evidence-based therapeutic strategy has not been establi
Externí odkaz:
https://doaj.org/article/0785efc327654eac925519345becb681
Autor:
Adila Abulizi, Guangpeng Yan, Qian Xu, Reyihanguli Muhetaer, Shihan Wu, Kudelaiti Abudukelimu, Xi Chen, Chengjiang Liu, Jun Li
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract While some literature has provided limited information about the potential cardiovascular risk and immune-related adverse events (irAEs) risk associated with PD-1/PD-L1 inhibitors in the treatment of Head and Neck Squamous Cell Carcinoma (HN
Externí odkaz:
https://doaj.org/article/f6f2208cb39d48a38ce7d53b406b19f7
Autor:
Flaviu Muresan, Olga Hilda Orasan, Angela Cozma, Madalina Daiana Bancos, Lorena Ciumarnean, Mircea Vasile Milaciu, Tinca Codruta Pocol, Nicoleta Valentina Leach, Teodora Gabriela Alexescu, Ovidiu Vasile Fabian, George Ciulei, Mirela Georgiana Perne
Publikováno v:
Journal of Mind and Medical Sciences, Vol 11, Iss 2, Pp 337-344 (2024)
Immune checkpoint inhibitors (ICIs) are an effective immunotherapeutic approach for cancers affecting the lung, skin, kidney, mammary gland, or certain hematologic malignancies. Regarding the prognosis of these oncological conditions, treatments with
Externí odkaz:
https://doaj.org/article/fa7293bd14384acfad4fff1208595747
Autor:
Parneet K. Cheema, Marco A. J. Iafolla, Husam Abdel-Qadir, Andrew B. Bellini, Nazira Chatur, Natasha Chandok, Vikram R. Comondore, Morven Cunningham, Ilana Halperin, Anne B. Hu, Diana Jaskolka, Saeed Darvish-Kazem, Masud H. Khandaker, Abhijat Kitchlu, Jasdip S. Sachdeva, Shane Shapera, Nicholas R. J. Woolnough, Massey Nematollahi
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 6356-6383 (2024)
The increased use of immune checkpoint inhibitors (ICIs) across cancer programs has created the need for standardized monitoring and management of immune-related adverse events (irAEs). Delayed recognition without appropriate treatment can have serio
Externí odkaz:
https://doaj.org/article/3e38519628c5425cabe1255ed3c8d53e
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 1222-1228 (2024)
Introduction: Immune-check-point inhibitors (ICIs) are established in the treatment of many malignancies. Many immune-related adverse events (irAEs) are well described; however, there is less information about opportunistic infections in cancer patie
Externí odkaz:
https://doaj.org/article/0612a8e2ca8245a98e123e16bc45342d
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-9 (2024)
Abstract Purpose Immune checkpoint inhibitors (ICIs) have improved lung cancer treatment but are associated with immune-related adverse events (irAEs). This study analyzes the relationship between irAEs and treatment effectiveness in advanced non-sma
Externí odkaz:
https://doaj.org/article/24f89ff893744ad6999c19926809fba4
Autor:
Giulia Santo, Maria Cucè, Antonino Restuccia, Teresa Del Giudice, Pierfrancesco Tassone, Francesco Cicone, Pierosandro Tagliaferri, Giuseppe Lucio Cascini
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background Direct comparisons between [18F]FDG PET/CT findings and clinical occurrence of immune-related adverse events (irAEs) based on independent assessments of clinical and imaging features in patients receiving immune checkpoint inhibit
Externí odkaz:
https://doaj.org/article/681776c01ddf48168bd78a87739e6a00
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 1034-1041 (2024)
Introduction: Immune checkpoint inhibitors can cause immune-related adverse events in various organ systems, with myocarditis being the most serious and life-threatening. This article reports three cases of immune myocarditis induced by camrelizumab,
Externí odkaz:
https://doaj.org/article/a96a1059c6de45c6893f5019d4eada6e
Publikováno v:
BMC Nephrology, Vol 25, Iss 1, Pp 1-13 (2024)
Abstract Background Although the patient survival rate for many malignancies has been improved with immune checkpoint inhibitors (ICIs), some patients experience various immune-related adverse events (irAEs). IrAEs impact several organ systems, inclu
Externí odkaz:
https://doaj.org/article/73b46763138143ec862ff0947d06126a